Skip to main content

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten Jetzt einloggen oder neu registrieren

Literatur

Literatur

  1. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Jama 298:194–206PubMedView Article
  2. Arnolds S, Dellweg S, Clair J et al. (2010) Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33:1509–1515PubMedView Article
  3. Beil W (2011) Drei DPP-4-Hemmer im Vergleich: Gemeinsamkeiten und Unterschiede. Diabetes Stoffw Herz 20:79–84
  4. Buse JB, Bergenstal RM, Glass LC et al. (2011) Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154:103–112PubMed
  5. Buse JB, Drucker DJ, Taylor KL et al. (2010) DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33:1255–1261PubMedView Article
  6. Davidson JA (2010) Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 85:S27–37PubMedView Article
  7. Elashoff M, Matveyenko AV, Gier B et al. (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150–156PubMedView Article
  8. Fakhoury WK, Lereun C, Wright D (2010) A meta-analysis of placebocontrolled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 86:44–57PubMedView Article
  9. Fonseca VA (2011) Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. Am J Med 124:S54–61PubMedView Article
  10. Gilbert MP, Pratley RE (2009) Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Eur J Intern Med 20 Suppl 2:S309–318PubMedView Article
  11. Inzucchi SE, Mcguire DK (2008) New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117:574–584PubMedView Article
  12. Jax T (2009) Treatment of patients with diabetes with GLP-1 analogues or DPP-4-inhibitors: a hot topic for cardiologists? Clin Res Cardiol 98:75–79PubMedView Article
  13. Johansen OE, Whitfield R (2008) Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 66:568–569PubMedView Article
  14. Lane W, Weinrib S, Rappaport J (2011) The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin Requirements. Diabetes Technol Ther
  15. Levin PA, Mersey JH, Zhou S et al. (2011) Clinical Outcomes Using Long-Term Combination Therapy With Insulin Glargine and Exenatide In Patients With Type 2 Diabetes. Endocr Pract:1–28
  16. Lopez-Ruiz A, Del Peso-Gilsanz C, Meoro-Aviles A et al. (2010) Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci 32:559–561PubMedView Article
  17. Matthaei S (2010) Behandlung des Diabetes mellitus Typ 2. Diabetologie 5:S127–S132View Article
  18. Matthaei S (2009) Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Diabetologie 4:32–64View Article
  19. Merker L (2011) Prävalenz der chronischen Nierenerkrankung bei Typ 2 Diabetikern in hausärztlicher Behandlung in Deutschland - erste Ergebnisse der PräDiane-Studie. Diabetes Stoffwechsel 6:S1–S102View Article
  20. Morrow L, Hompesch M, Guthrie H et al. (2011) Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 13:75–80PubMedView Article
  21. Nathan D, Buse J, Davidson M et al. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52:17–30PubMedView Article
  22. Nauck M, Frid A, Hermansen K et al. (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84–90PubMedView Article
  23. Nauck MA, Vardarli I, Deacon CF et al. (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54:10–18PubMedView Article
  24. Pratley RE (2008) Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 10:171PubMed
  25. Richter B, Bandeira-Echtler E, Bergerhoff K et al. (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester, UK
  26. Saxena R, Hivert MF, Langenberg C et al. (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142–148PubMedView Article
  27. Weise WJ, Sivanandy MS, Block CA et al. (2009) Exenatide-associated ischemic renal failure. Diabetes Care 32:e22–23PubMedView Article
Über diesen Artikel